Amit Bhardwaj

Amit Bhardwaj has a diverse work experience in the field of research and biotechnology. Starting in 2001, they worked as a Research Associate at ICGEB until 2005. Amit then went on to pursue their PhD, focusing on the study of a thermostable family 10 xylanase. During their PhD, they utilized biochemical, biophysical, and proteomic approaches to understand the role of N- and C-terminal aromatic cluster interaction in GH10 xylanase protein stability and folding. After completing their PhD in 2010, Amit joined ICGEB as a Post Doctoral Fellow. Amit'sresearch revolved around studying the molecular basis of TDP-RNA interactions and their involvement in RNA processing. In 2014, they moved to NYU Langone Health, where they initially worked as a Postdoctoral Researcher, contributing significantly to the field of tankyrase research. Amit'sachievements include designing and performing a quantitative proteomic screen to identify the role of tankyrase and developing the first-ever human tankyrase knockout cell lines using CRISPR-Cas9. Amit was also involved in successful collaborations and published their work within the timeframe. Finally, in 2021, they joined Halda Therapeutics as a Senior Research Scientist, where they currently work.

Amit Bhardwaj completed their education from 2005 to 2010 at Delhi University, where they obtained a PhD in Biochemistry and Molecular Biology.